Close Menu

Biogen

Led by a group of 10 biopharmaceutical firms, the project will use Olink's proteomic technology to look at participants' plasma levels of roughly 1,500 proteins.

But, Again, Maybe Not

An FDA advisory panel has determined there isn't enough data to gauge whether a new Alzheimer's disease drug works, according to NPR.

Seems to Support

According to Stat News, US regulators appear to have a favorable view of Biogen's Alzheimer's disease therapy.

Far Spread

The Boston Globe reports Biogen's February conference may have been a COVID-19 super-spreader event.

The biobank will collect samples and data from Biogen employees who contracted and have recovered from COVID-19, as well as their family members and close contacts.

Closed to Clean

The Hill reports PhRMA has closed its headquarters for the week to clean following after a visitor tested positive for SAR-CoV-2.

The consortium aims to develop assays that can detect biomarkers of pulmonary fibrosis that can be used as early indicators of a treatment's activity.

Bringing It Back

Time magazine discusses Biogen's move to resurrect its Alzheimer's disease drug.

Regeneron Pharmaceuticals and its collaborators plan to sequence the exomes all of the UK Biobank participants by then end of 2019.

By the end of 2019, Regeneron plans sequence the exomes of all 500,000 participants in the UK Biobank.

Pages

Reuters reports that Germany is seeking to sequence 5 percent of patient samples that test positive for SARS-CoV-2.

23andMe and Medscape say primary care physicians are increasingly more comfortable with discussing direct-to-consumer genetic testing results.

The publisher of the Science family of journals will allow some authors to place peer-reviewed versions of their papers into publicly accessible repositories.

In Science this week: analysis of genome-wide association studies of chronic kidney disease, and more.